Mechanism of ascorbic acid enhancement of the bioavailability and diuretic effect of furosemide

Drug Metabolism and Disposition

Volumn 26, Issue 5, 1998, Pages 401-407

  Lee, Myung G ^b   Chiou, Win L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; FUROSEMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DIURESIS; DRUG DISPOSITION; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME METABOLISM; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; KIDNEY TUBULE EPITHELIUM; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ASCORBIC ACID; BIOLOGICAL AVAILABILITY; DIURETICS; DOGS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUROSEMIDE; INTESTINAL ABSORPTION; MALE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031950231     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Andreasen F, Boetker HE and Lorentzen K (1982) In vitro studies in the hydrolysis of furosemide in gastrointestinal juices. Br J Clin Pharmacol 14:306-309.
2. Beermann B, Dalén E, Lindström B and Rosén A (1973) On the fate of furosemide in man. Eur J Clin Pharmacol 9:57-61.
3. Benet LZ (1979) Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm 7:1-27.
4. Boles Ponto LL and Schoenwald RD (1990a) A pharmacokinetic/pharmacodynamic review. I. Clin Pharmacokinet 18:381-408.
5. Boles Ponto LL and Schoenwald RD (1990b) A pharmacokinetic/pharmacodynamic review. II. Clin Pharmacokinet 18:460-471.
6. Branch RA, Roberts CJC, Homeida M and Levine D (1977) Determinants of response to furosemide in normal subjects. Br J Clin Pharmacol 4:121-127.
7. Brater DC (1983) Clinical use of loop diuretics. Hosp Form Oct:962-975.
8. Brater DC, Seiwell R, Andreasen S, Burdett A, Dekmer GJ and Chennavasin P (1982) Absorption of fursemide in congestive heart failure. Kidney Int 22:171-176.
9. Chiou WL (1978) Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
10. Chiou WL (1980) New calculation method of mean total body clearance of drugs and application to rational dosage regimens. J Pharm Sci 69:90-91.
11. Chungi VS, Dittert LW and Smith RS (1979) Gastrointestinal sites of furosemide absorption in rats. Im J Pharm 4:27-38.
12. Cruz JE, Maness DD and Yakatan JG (1979) Kinetics and mechanism of hydrolysis of furosemide. Int J Pharm 2:275-281.
13. Domingo JL, Gomes M, Llobert JM, del Castillo D and Corbella J (1994) Influence of citric, ascorbic and lactic acids on the gastrointestinal absorption of aluminum in uremic rats. Nephron 66:108-109.
14. Eatman FB, Colburn WA, Boxenbaum HG, Weissman L, Moore JD, Gibaldi M and Kaplan SA (1977) Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
15. Fuller R, Hoppel C and Ingalls ST (1981) Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clin Pharmacol Ther 30:461-467.
16. Gibaldi M and Perrier D (1982) Pharmacokinetics, ed 2. Dekker, New York.
17. Giebisch G (1978) Effects of diuretics on renal transport potassium, in Methods of Pharmacology, vol 4A (Martines-Maldonado M ed), pp 121-164, Plenum, New York.
18. Gonzalez JP, Valdivieso A, Calvo R, Rodriguez-Sasiain JM, Jimenez R, Aquirre C and du Souich P (1995) Influence of vitamin C on the absorption and first-pass metabolism of propranolol. Eur J Clin Pharmacol 48:295-297.
19. Green TP and Mirkin BL (1981) Furosemide disposition in normal and proteinuretic rats: urinary protein binding as a determinant of drug excretion. J Pharmacol Exp Ther 218:122-127.
20. Hammerlund-Udenaes M and Benet LZ (1989) Furosemide pharmacokinetics and pharmacodynamics in health and disease: an update. J Pharmacokinet Biopharm 17:1-46.
21. Jang SH, Lee MG and Kim ND (1994) Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. Biopharm Drug Dispos 15:185-206.
22. Kahn T, Kaufman AM and Mac-Moune FL (1983) Response to repeated furosemide administration on low chloride and low sodium intake in the rat. Clin Sci 64:565-572.
23. Kelly MR, Cutler RE, Forry AW and Kimpel BM (1974) Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther 15:178-186.
24. Kim SH, Choi YM and Lee MG (1993) Pharmacokinetics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-27.
25. Lee MG (1982) Absorption and disposition of furosemide, Ph.D. thesis, University of Illinois at Chicago, Chicago, IL.
26. Lee MG, Chen M-L and Chiou WL (1981) Pharmacokinetics of drugs in blood. II. Unusual distribution and storage effect of furosemide. Res Commun Chem Pathol Pharmacol 34:17-28.
27. Lee MG and Chiou WL (1983) Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
28. Lee MG, Li T and Chiou WL (1986) Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. Biopharm Drug Dispos 7:537-547.
29. Li T, Lee MG and Chiou WL (1986) Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. J Pharmacokinet Biopharm 14:495-509.
30. Litterst CL, Mimnaugh EG, Reagan RI and Gram TE (1975) Comparison of in vitro drug metabolism by lung, liver and kidney of several common laboratory species. Drug Metab Dispos 3:259-265.
31. Matsuki Y, Hongu Y, Noda Y, Kiwada H, Sakurai H and Goromaru T (1992) Effects of ascorbic acid on the metabolic fate and the free radical formation of iproniazid. Yakugaku Zasshi 112:926-933.
32. Michell JR, Nelson WL, Fotter WI, Sasame HA and Jollow DJ (1976) Metabolic activation of furosemide to a chemically reactive hepatotoxic metabolite. J Pharmacol Exp Ther 199:42-52.
33. Odlind BO (1980) Diuretic resistance: reduced bioavailability and effect of oral furosemide. Br Med J 280:1577.
34. Prasad VK, Rapaka RS, Knight PW and Cabana BE (1982) Dissolution medium: a critical parameter to identify bioavailability problems of furosemide tablet. Int J Pharm 11:81-90.
35. Rogers SM, Back DJ and Orme MLE (1987) Intestinal metabolism of ethinyl estradiol and paracetamol in vitro: studies using Ussing chambers. Br J Clin Pharmacol 23:727-734.
36. Shore PA, Brodie BB and Hogben CAM (1957) The gastric secretion of drugs: a pH-partition hypothesis. J Pharmacol Exp Ther 119:361-369.
37. Smith DE, Lin EC and Benet LZ (1981) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Dispos 8:337-342.
38. Verbeeck RK, Gerkens JF, Wilkinson GP and Branch RA (1981) Disposition of furosemide in functionally hepatectomized dogs. J Pharmacol Exp Ther 216:479-483.
39. Waller ES, Hamilton SF, Massarella JW, Scharanevych MA, Smith RV, Yakatan GJ and Doluisio JT (1982) Disposition and absolute bioavailability of furosemide in healthy males. J Pharm Sci 71:1105-1108.
40. Yakatan GJ, Maness DD, Scholler J, Novick WJ Jr and Doluisio T (1976) Absorption, distribution, metabolism, and excretion of furosemide in dogs and monkeys. I. Analytical methodology, metabolism, and urinary excretion. J Pharm Sci 45:1456-1460.